Stay updated with breaking news from Provent Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase III trial shows Evusheld (tixagevimab and cilgavimab) reduces the risk of developing symptomatic COVID-19 in vulnerable populations.
TOP NEWS: Astra's Covid-19 antibody drug Evusheld gets approval in US | Financial News
LONDON BRIEFING: Softbank's Fortress doesn't give up on Morrisons | Financial News
LONDON MARKET PRE-OPEN: Astra works on Covid cocktail; UK sales falter | Financial News